Clinical application of ctDNA in early diagnosis, treatment and prognosis of patients with non-small cell lung cancer

Zhu, Shenyu; Wu, Rongqian; Liu, Xiangjin; Xie, Bin; Xie, Chunfa; Li, Shulin; Wu, Zhicheng; Zhang, Zuxiong; Tang, Zhixian; Gu, Liang

doi:10.1080/14796694.2024.2376513

Future Oncology

2024

DOI: 10.1080/14796694.2024.2376513

|View full text |Cite

Clinical application of ctDNA in early diagnosis, treatment and prognosis of patients with non-small cell lung cancer

Shenyu Zhu,

Rongqian Wu,

Xiangjin Liu

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 99 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Clinical applications of circulating biomarkers in non-small cell lung cancer

Oh,

Imam-Aliagan,

Kim

et al. 2024

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Despite recent advances in cancer diagnostics and treatment, the mortality associated with lung cancer is still the highest in the world. Late-stage diagnosis, often accompanied by metastasis, is a major contributor to the high mortality rates, emphasizing the urgent need for reliable and readily accessible diagnostic tools that can detect biomarkers unique to lung cancer. Circulating factors, such as circulating tumor DNA and extracellular vesicles, from liquid biopsy have been recognized as diagnostic or prognostic markers in lung cancer. Numerous clinical studies are currently underway to investigate the potential of circulating tumor DNA, circulating tumor RNA, exosomes, and exosomal microRNA within the context of lung cancer. Those clinical studies aim to address the poor diagnostics and limited treatment options for lung cancer, with the ultimate goal of developing clinical markers and personalized therapies. In this review, we discuss the roles of each circulating factor, its current research status, and ongoing clinical studies of circulating factors in non-small cell lung cancer. Additionally, we discuss the circulating factors specifically found in lung cancer stem cells and examine approved diagnostic assays designed to detect circulating biomarkers in lung cancer patients.

show abstract

Clinical applications of circulating biomarkers in non-small cell lung cancer

Oh,

Imam-Aliagan,

Kim

et al. 2024

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Clinical application of ctDNA in early diagnosis, treatment and prognosis of patients with non-small cell lung cancer

Cited by 1 publication

References 99 publications

Clinical applications of circulating biomarkers in non-small cell lung cancer

Clinical applications of circulating biomarkers in non-small cell lung cancer

Contact Info

Product

Resources

About